Accumetrics Teams Up With Big Pharma To Push Platelet Function Testing
This article was originally published in The Pink Sheet Daily
Executive Summary
VerifyNow test maker Accumetrics will collaborate with Effient co-marketers Eli Lilly and Daiichi Sankyo to launch a clinician awareness campaign that highlights the value of monitoring patient response to antiplatelet drugs.
You may also be interested in...
Aggressive Antiplatelet Agents May Not Have Place In Low-Risk PCI Populations
The discontinuation of Lilly & Co./Daiichi Sankyo Ltd. Co.'s TRIGGER-PCI trial of Effient because of a low level of events in the patient population is consistent with the findings of the earlier GRAVITAS study of personalized therapy with Plavix, and may indicate that aggressive management isn't needed in lower risk patients after percutaneous coronary intervention.
Aggressive Antiplatelet Agents May Not Have Place In Low-Risk PCI Populations
The discontinuation of Lilly & Co./Daiichi Sankyo Ltd. Co.'s TRIGGER-PCI trial of Effient because of a low level of events in the patient population is consistent with the findings of the earlier GRAVITAS study of personalized therapy with Plavix, and may indicate that aggressive management isn't needed in lower risk patients after percutaneous coronary intervention.
GRAVITAS Fails To Show Clinical Value Of Platelet Function Testing For Plavix
Study results don't prove clinical benefit for point-of-care testing, but trial may not have been sufficiently powered to show a difference.